|
Current Iodine Deficiency Disorder Situation
Population
Population: 3.33 million
Population growth rate: -0.15%
Population < 15 years: 22.2%
Birth rate: 12 per 1000
Life expectancy at birth: 66.6 years
Infant mortality: 41.1 per 1000
Prevalence of Goiter/ UIE
Median urinary iodine: > 100 mcg/L. National surveys concluded that mild to moderate deficiency existed as of 1997. In a national survey in 1998, the urinary iodine iodine level was > 100 mcg/L, and the goiter rate in women and children was up to 30%. The distribution among categories was: < 20 mcg/L, 0.79%; 20-49 mcg/L, 8.1%; 50-99 mcg/L, 22.8%; 100-1000 mcg/L, 68.3%; > 1000 mcg/L, 0.01%.
Iodized salt Coverage
Household iodized salt use: 84% (2000)
Salt Situation Analysis Production
One manufacturer exists, with a capacity of 52,000 tons. Production for local needs only is 15,000 tons. Some salt is imported from Iran and repackaged.
Universal salt iodization is currently carried out mainly at the initiative of the country's single salt producer. Details on salt quality control and the impact of iodization are needed.
Consumption
Overall 84% of households consume iodized salt (DHS 2000), but in some regions (Lori, Shirak, Tavush) 24-27% of samples had no iodine.. Iodine Procurement and Utilization
All edible salt produced in the country is reported to be iodized with KIO3 at 50 ppm (1998).
Universal Salt Iodization Program
Information, Education, Communication (IEC) Activities
Legislation
None, still pending. Program Monitoring and Evaluation
Probably iodine sufficient but no formal program, oversight or impact monitoring. Quality control systems for iodized salt are established on production and distribution levels by the government. Urinary iodine laboratories are available. No regular impact monitoring.
Other Interventions None
Key Lessons Learned
Challenges and Constraints
Future Plans for Sustained IDD Elimination
Sources:
IDD NL 18(3):33, 2002
IDD NL 13(1), 1997 |
